PQ6.F Starpharma Holdings Limited

Healthcare Biotechnology Frankfurt Exchange
0.2480 EUR
Close of Nov 12, 2026
0.1660 0.5200
Market cap
EUR 120M
P/E
-
P/B
14.14x
ROE
-54.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is PQ6.F undervalued?

Graham number

The Graham number of Starpharma Holdings Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Starpharma Holdings Limited fundamental analysis

No fundamental analysis for Starpharma Holdings Limited yet.

Starpharma Holdings Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Starpharma Holdings Limited

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating.…

Full company profile